These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 9751627

  • 1. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP.
    Cancer Res; 1998 Sep 15; 58(18):4146-54. PubMed ID: 9751627
    [Abstract] [Full Text] [Related]

  • 2. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA.
    Cancer Res; 1995 Aug 01; 55(15):3369-73. PubMed ID: 7614473
    [Abstract] [Full Text] [Related]

  • 3. Development of an immunocytokine, IL-2-183B2scFv, for targeted immunotherapy of ovarian cancer.
    Zhang X, Feng J, Ye X, Yao Y, Zhou P, Chen X.
    Gynecol Oncol; 2006 Dec 01; 103(3):848-52. PubMed ID: 16806435
    [Abstract] [Full Text] [Related]

  • 4. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR.
    Cancer Res; 1994 May 01; 54(9):2448-55. PubMed ID: 7512887
    [Abstract] [Full Text] [Related]

  • 5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ.
    Cancer Res; 2000 Aug 15; 60(16):4475-84. PubMed ID: 10969795
    [Abstract] [Full Text] [Related]

  • 6. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
    Altenschmidt U, Klundt E, Groner B.
    J Immunol; 1997 Dec 01; 159(11):5509-15. PubMed ID: 9548491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting human T-lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice.
    Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR.
    Cancer Res; 1990 Jul 15; 50(14):4227-32. PubMed ID: 2142014
    [Abstract] [Full Text] [Related]

  • 11. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
    Cho BK, Roy EJ, Patrick TA, Kranz DM.
    Bioconjug Chem; 1997 Jul 15; 8(3):338-46. PubMed ID: 9177839
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
    Rohrbach F, Gerstmayer B, Biburger M, Wels W.
    Clin Cancer Res; 2000 Nov 15; 6(11):4314-22. PubMed ID: 11106249
    [Abstract] [Full Text] [Related]

  • 15. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.
    Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, Nickerson PW, Li Y, Tian Y, Strom TB.
    J Immunol; 1999 Oct 01; 163(7):4041-8. PubMed ID: 10491008
    [Abstract] [Full Text] [Related]

  • 16. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M, Zhang L, Gu HT, Jiang FQ, Qian L, Yu M, Chen GJ, Luo Q, Shen BF, Guo N.
    Acta Pharmacol Sin; 2007 Oct 01; 28(10):1611-20. PubMed ID: 17883948
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG.
    Cancer Res; 2009 Dec 01; 69(23):8987-95. PubMed ID: 19934334
    [Abstract] [Full Text] [Related]

  • 19. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS, Penichet ML, Morrison SL.
    J Immunol; 1999 Jul 01; 163(1):250-8. PubMed ID: 10384123
    [Abstract] [Full Text] [Related]

  • 20. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D.
    Cancer Res; 2003 Jun 15; 63(12):3202-10. PubMed ID: 12810649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.